课题基金 / 基金详情

ANTIRETROVIRAL THERAPY ON BODY COMPOSITION IN HIV-INFECTED CHILDREN

ANTIRETROVIRAL THERAPY ON BODY COMPOSITION IN HIV-INFECTED CHILDREN
抗逆转录病毒治疗对艾滋病毒感染儿童身体成分的影响
批准号:
7378255
负责人:
William Borkowsky
金额:
$0.33万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-04-01 至 2007-03-31

项目摘要

项目成果

William Borkowsky的其他基金

相似基金

相关文献

中文摘要
翻译
该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者(PI)可能从另一个NIH来源获得了主要资金,因此可以在其他CRISP条目中表示。所列机构为中心,不一定是研究者所在机构。消瘦综合征是导致感染艾滋病毒儿童死亡的一个重要因素。关于艾滋病毒感染儿童的身体组成或抗逆转录病毒治疗后的变化的信息很少,生长和病毒载量之间的关系仍然不清楚。PACTG 1010是一项多中心观察性试验,由国家过敏和传染病研究所(NIAID)和国家儿童健康和人类发育研究所(NICHD),NIH通过儿科临床试验合作组支持。这是一项观察性研究,测量青春期前感染艾滋病毒的儿童的身体成分、生长和营养参数。将在不同疾病阶段的患者中获得许多参数(血液水平、生物电阻抗分析、身体测量等)。抗逆转录病毒应答者将与无应答者进行比较。截至2003年1月3日,本研究招募了70例受试者,9例受试者进入A层(1至18个月),12例受试者进入B层(年龄大于18个月至3岁),24例进入C层(年龄大于3岁至8岁),25例进入D层(年龄大于8岁至13岁)。研究继续招募受试者。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Wasting syndrome is a significant contributor to mortality in HIV-infected children. Little information is available on body composition in HIV-infected children or changes upon institution of antiretroviral therapy, and the relationship between growth and viral load remains unclear. PACTG 1010 is a multi-site observational trial supported by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Child Health and Human Development (NICHD), NIH, through the Pediatric Clinical Trials Cooperative Group. It is an observational study measuring body composition, growth and nutritional parameters in pre-puberty children with HIV infection. Numerous parameters (blood levels, bioelectrical impedance analysis, body measures, etc) will be obtained in patients at various stages of disease. Antiretroviral responders will be compared with non-responders. As of January 3, 2003, the study has accrued 70 subjects, nine subjects into Stratum A (1 to 18 months of age), 12 subjects into Stratum B (older than 18 months to three years of age), 24 into Stratum C (older than three years to eight years of age), 25 into Stratum D (older than eight years to 13 years of age). Subjects continue to be recruited for the study.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Virology Core
CLINICAL TRIAL: PACTG 390: ANTIRETROVIRAL REGIMENS AND TREATMENT-SWITCHING STRAT
CLINICAL TRIAL: PACTG 1020-A: NOVEL PROTEASE INHIBITOR (BMS-232632) IN HIV-INFEC
CLINICAL TRIAL: PACTG 1025: PERINATAL CORE PROTOCOL (AIDS)
海外基金